Wasatch Advisors Has Cut Its Holding in Macrogenics (MGNX) by $335,175 as Stock Declined; Birchview Capital LP Stake in Celgene (Celg) (CELG) Has Cut as Market Valuation Declined

June 19, 2018 - By Ellis Scott

Celgene Corporation (NASDAQ:CELG) Logo

Birchview Capital Lp decreased its stake in Celgene Corp (Celg) (CELG) by 4.69% based on its latest 2018Q1 regulatory filing with the SEC. Birchview Capital Lp sold 34,870 shares as the company’s stock declined 18.51% with the market. The institutional investor held 709,181 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $63.27 million, down from 744,051 at the end of the previous reported quarter. Birchview Capital Lp who had been investing in Celgene Corp (Celg) for a number of months, seems to be less bullish one the $57.48 billion market cap company. The stock increased 2.02% or $1.57 during the last trading session, reaching $79.3. About 6.23 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 19, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 18/05/2018 – FDA Warns of Decreased Survival in Keytruda, Tecentriq Trials; 04/05/2018 – CELGENE CORP – SEES FY 2018 POMALYST/IMNOVID NET PRODUCT SALES WITHOUT DILUTION FROM JUNO TO BE ABOUT $2.0 BLN; 27/04/2018 – AnaptysBio To Participate in Upcoming Investor Conferences; 06/03/2018 – BRISTOL-MYERS SQUIBB – FDA APPROVES OPDIVO LABEL UPDATE OFFERING FLEXIBLE FLAT-DOSING OPTIONS EVERY TWO WEEKS (240 MG) OR EVERY FOUR WEEKS (480 MG); 24/05/2018 – MOODY’S: CELGENE’S ACCELERATED SHR REPURCHASE CREDIT NEGATIVE; 23/05/2018 – Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line; 19/04/2018 – Celgene: Patricia Hemingway Hall Elected to Bd of Directors; 09/04/2018 – CELG: Celgene M&A targets may include Agios, Jounce, FT reports; 21/05/2018 – EVOTEC AG EVTG.DE – EVOTEC MAY BE ELIGIBLE TO RECEIVE SIGNIFICANT MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON EACH LICENSED PROGRAMME

Wasatch Advisors Inc decreased its stake in Macrogenics Inc. (MGNX) by 1.3% based on its latest 2018Q1 regulatory filing with the SEC. Wasatch Advisors Inc sold 13,407 shares as the company’s stock declined 7.73% with the market. The institutional investor held 1.02M shares of the health care company at the end of 2018Q1, valued at $25.54 million, down from 1.03M at the end of the previous reported quarter. Wasatch Advisors Inc who had been investing in Macrogenics Inc. for a number of months, seems to be less bullish one the $965.16 million market cap company. The stock increased 1.96% or $0.44 during the last trading session, reaching $22.87. About 147,921 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 19.62% since June 19, 2017 and is uptrending. It has outperformed by 7.05% the S&P500. Some Historical MGNX News: 23/04/2018 – European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed; 18/05/2018 – U.S. FDA – ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB); 07/05/2018 – Macrogenics 1Q Loss/Shr $1.34; 14/03/2018 – MACROGENICS INC MGNX.O : MORGAN STANLEY RAISES TARGET PRICE TO $26 FROM $18; 09/05/2018 – Provention Bio Announces Agreements with MacroGenics for Two Clinical-Stage Assets for the Treatment of Autoimmune Disorders; 09/04/2018 – KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor…; 07/05/2018 – MACROGENICS INC – QTRLY NET LOSS PER COMMON SHARE $1.34; 16/04/2018 – Combination Of Pembrolizumab And Chemotherapy Doubles Survival In Patients With Metastatic Lung Cancer; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE…

Investors sentiment increased to 1.79 in Q1 2018. Its up 0.68, from 1.11 in 2017Q4. It increased, as 13 investors sold MGNX shares while 25 reduced holdings. 30 funds opened positions while 38 raised stakes. 31.74 million shares or 12.30% more from 28.26 million shares in 2017Q4 were reported. Mackay Shields owns 20,638 shares. Alliancebernstein Limited Partnership holds 41,700 shares or 0% of its portfolio. Employees Retirement Sys Of Ohio has invested 0.01% in MacroGenics, Inc. (NASDAQ:MGNX). Citigroup stated it has 0% in MacroGenics, Inc. (NASDAQ:MGNX). Invesco Ltd has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Commercial Bank Of America De holds 25,554 shares or 0% of its portfolio. Cubist Systematic Strategies Lc has 25,312 shares for 0.04% of their portfolio. Granite Point Lp accumulated 40,000 shares or 0.1% of the stock. Hood River Capital Management Llc, a Oregon-based fund reported 646,109 shares. Voya Inv Ltd Company has invested 0.02% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Dekabank Deutsche Girozentrale reported 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). United Kingdom-based Legal General Group Inc Public Ltd has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Ecor1 Lc accumulated 3.66% or 1.45M shares. Td Asset Mgmt invested in 0% or 43,339 shares. Moreover, Prelude Cap Mngmt Ltd Co has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 254 shares.

Since January 16, 2018, it had 0 insider buys, and 7 sales for $1.10 million activity. The insider Risser Eric Blasius sold $25,005. Another trade for 23,967 shares valued at $599,436 was made by Cilinski Lynn on Wednesday, February 28. Karrels James had sold 5,000 shares worth $155,000.

More recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: Nasdaq.com which released: “MacroGenics to Present at Jefferies Global Healthcare Conference” on June 05, 2018. Also Seekingalpha.com published the news titled: “Premarket analyst action – healthcare” on May 31, 2018. Nasdaq.com‘s news article titled: “New Research Coverage Highlights Materialise NV, MacroGenics, GasLog Partners LP, TCP Capital, NantHealth, and …” with publication date: June 06, 2018 was also an interesting one.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on August, 1. They expect $-1.20 earnings per share, down 5.26% or $0.06 from last year’s $-1.14 per share. After $-1.34 actual earnings per share reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -10.45% EPS growth.

Wasatch Advisors Inc, which manages about $19.28B and $7.74B US Long portfolio, upped its stake in Prosperity Bancshares Inc. (NYSE:PB) by 9,607 shares to 237,457 shares, valued at $17.25 million in 2018Q1, according to the filing. It also increased its holding in Heico Corp. (NYSE:HEI.A) by 251,697 shares in the quarter, for a total of 1.67 million shares, and has risen its stake in Ishares Msci India Etf (INDA).

Among 12 analysts covering MacroGenics (NASDAQ:MGNX), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. MacroGenics had 26 analyst reports since August 6, 2015 according to SRatingsIntel. As per Monday, September 11, the company rating was maintained by Stifel Nicolaus. Janney Capital initiated MacroGenics, Inc. (NASDAQ:MGNX) on Thursday, February 18 with “Buy” rating. The firm has “Neutral” rating by Citigroup given on Thursday, August 4. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Equal-Weight” rating given on Wednesday, March 14 by Morgan Stanley. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, August 7. SunTrust initiated it with “Buy” rating and $30 target in Tuesday, December 20 report. BTIG Research maintained MacroGenics, Inc. (NASDAQ:MGNX) on Friday, January 19 with “Buy” rating. Stifel Nicolaus maintained MacroGenics, Inc. (NASDAQ:MGNX) on Thursday, August 6 with “Buy” rating. Leerink Swann maintained the stock with “Buy” rating in Wednesday, October 25 report. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Buy” rating given on Friday, September 1 by SunTrust.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 21 have Buy rating, 1 Sell and 13 Hold. Therefore 60% are positive. Celgene Corporation had 151 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, October 27 by UBS. BMO Capital Markets maintained the stock with “Outperform” rating in Tuesday, October 17 report. The rating was downgraded by RBC Capital Markets on Monday, May 7 to “Outperform”. The firm has “Buy” rating given on Thursday, September 14 by Jefferies. The firm earned “Neutral” rating on Friday, October 27 by Citigroup. The rating was maintained by Credit Suisse on Wednesday, February 28 with “Outperform”. Oppenheimer maintained the shares of CELG in report on Wednesday, June 14 with “Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Stifel Nicolaus on Thursday, September 7. PiperJaffray reinitiated Celgene Corporation (NASDAQ:CELG) on Monday, October 23 with “Neutral” rating. On Friday, July 28 the stock rating was maintained by Leerink Swann with “Outperform”.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Tandem Diabetes Care Has Run Up A Lot – Cramer’s Lightning Round (6/15/18)” on June 18, 2018, also Seekingalpha.com with their article: “Will ‘Public Shaming’ Sink Celgene?” published on May 21, 2018, Seekingalpha.com published: “Finger-Pointing At Celgene” on June 14, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Goldman bearish on Celgene” published on May 25, 2018 as well as Fool.com‘s news article titled: “3 Top Biotech Stocks to Buy Right Now” with publication date: June 18, 2018.

Since February 8, 2018, it had 2 insider buys, and 5 sales for $5.91 million activity. Shares for $99,784 were bought by Alles Mark J on Tuesday, May 8. $1.26M worth of Celgene Corporation (NASDAQ:CELG) was sold by MARIO ERNEST on Friday, February 23. CASEY MICHAEL D had sold 13,000 shares worth $1.02M on Thursday, June 7. Shares for $1.77M were sold by KAPLAN GILLA.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 26. They expect $1.87 EPS, up 11.31% or $0.19 from last year’s $1.68 per share. CELG’s profit will be $1.36 billion for 10.60 P/E if the $1.87 EPS becomes a reality. After $1.61 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 16.15% EPS growth.

Investors sentiment decreased to 0.79 in Q1 2018. Its down 0.04, from 0.83 in 2017Q4. It worsened, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Dupont Cap Mngmt, a Delaware-based fund reported 179,283 shares. Sands Ltd Liability Corporation invested in 0.02% or 65,744 shares. Jennison Associates Limited Liability Com invested in 8.77 million shares. Horan Cap Advsrs Limited Company holds 28,165 shares or 1.65% of its portfolio. Private Advisor Gp Lc reported 0.22% of its portfolio in Celgene Corporation (NASDAQ:CELG). Koshinski Asset invested 0.39% in Celgene Corporation (NASDAQ:CELG). Janney Cap Mgmt holds 0.01% or 3,814 shares. Perigon Wealth Mngmt Lc invested in 1.19% or 36,083 shares. First Fincl Corp In reported 0.03% stake. Bedrijfstakpensioenfonds Voor De Media Pno invested in 115,000 shares or 1.68% of the stock. Kings Point Cap Mngmt invested in 2,400 shares or 0.04% of the stock. Saturna Cap has 0.6% invested in Celgene Corporation (NASDAQ:CELG). Montecito Financial Bank And Trust owns 3,925 shares. Terril Brothers accumulated 0.79% or 29,295 shares. 1832 Asset Management Limited Partnership holds 0.07% or 205,200 shares.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>